**S3 Table.** Baseline demographic and clinical characteristics of the 43 patients pre-included during the same period, who were not considered to have covid-19 by consensus, and not included in the prospective observational study.

|  |  |
| --- | --- |
| **Characteristics** | **Total** |
| Number n (%) | 43 |
| Median age (IQR) year | 57.5 (44.4-71.6) |
| Age category  |  |
|  <50 year | 16 (37.2) |
|  50 to <70 year | 10 (23.3) |
|  >=70 year | 17 (39.5) |
| Male sex  | 21 (48.8) |
| Geographic origin  |  |
|  Caucasian | 29 (67.5) |
|  Subsaharan | 9 (20.9) |
|  North African, Middle East | 5 (11.6) |
| Oxygen-support category  |  |
|  Invasive oxygen support | 0 (0-0) |
|  Noninvasive oxygen support | 3 (7.1) |
|  None | 37 (92.9) |
| Coexisting conditions  |  |
|  Hypertension | 21 (48.8) |
|  Diabetes | 14 (32.6) |
|  Hyperlipidemia | 15 (34.9) |
|  Liver disease | 9 (42.9) |
|  Pulmonary disease | 6 (14.0) |
|  Severe disease mixed | 31 (88.6) |
| Tobacco (ongoing or stopped) | 15 (34.9) |
| Alcohol consumption | 12 (30.3) |
| Median laboratory (IQR) |  |
| Apolipoprotein-A1 g/liter | 0.95 (0.73-1.23) |
| Haptoglobin g/liter | 1.91 (1.19-2.98) |
| Alpha-2 macroglobulin g/liter | 1.54 (1.29-1.99) |
| GGT IU per liter | 53 (26-114) |
| ALT IU per liter | 34 (23-55) |
| Total bilirubin micromol/L | 8 (4-18) |
| Platelets 106 per ml | 228 (165-314) |
| Creatinine µmol per liter | 74 (54-97) |
| Treatment at risk of DILI |  |
|  Paracetamol oral (2-4 g/day) | 7 (16.7) |
|  Antibiotics |  |
|  None | 34 (79.1) |
|  Without clavulinate | 5 (11.6) |
|  With clavulinate | 5 (9.3) |
|  Hydroxychloroquine (for sarcoidosis) | 1 (97.6) |
| Fibrosis stage by FibroTest (%) |  |
|  F0 <=0.27 | 17 (42.5) |
|  F1 <=0.48 | 8 (20.0) |
|  F2 <=0.58 | 3 (7.5) |
|  F3 <=0.68 | 1 (2.5) |
|  F4 <=0.74 | 11 (27.5) |
|  Non interpretable | 0 (0.0) |
|  Missing | 3 (7.0) |
|  |
|  |
|  |
|  |
|  |
|  |